gavilimomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458275362

| image =

| type = mab

| mab_type = mab

| source = o

| target = CD147

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 244096-20-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = TCR92293RC

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147. Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.{{cite journal | vauthors = Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR | display-authors = 6 | title = A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease | journal = Blood | volume = 109 | issue = 6 | pages = 2657–62 | date = March 2007 | pmid = 17110457 | doi = 10.1182/blood-2006-08-013995 | doi-access = free }}

It was originally developed by Abgenix,{{cite web | title = Gavilimomab | url = https://adisinsight.springer.com/drugs/800006000 | work = Adis Insight | publisher = Springer Nature Switzerland AG }} which was later acquired by Amgen.